TITRE III: Influenza B Immunogenicity Investigation

Inclusion criteria

• Child previously completed the TITRE I study in British Columbia or Quebec;
• Child is healthy (stable chronic conditions acceptable) as established by health assessment interview and verbal history-directed health examination;
• Child is available and can complete all relevant procedures during the study period;
• Parent or legal guardian is available and can be reached by phone during the study period;
• Parent/guardian provides written informed consent;
• Parent/guardian is fluent in English/French

Exclusion criteria

• Child has already received the 2018-19 seasonal (TIV or QIV) influenza vaccine;
• Child has a bleeding condition that would prevent vaccine injection or blood collection;
• Child has known or suspected immunodeficiency;
• Child has a suspected or known anaphylactic reaction to any of the vaccine components used in this study;
• Child has a health condition which, in the opinion of the investigator, would interfere with the evaluation or pose a health risk to the child;
• Child has received immune globulin or other blood products within the prior six weeks;
• Child has received injected or oral steroids within the prior six weeks defined by more than 1 week of immunosuppressants or immune modifying drugs (e.g. oral prednisolone >0.5mL/kg/day or intravenous glucocorticoid steroid). Nasal, topical or inhaled steroids are allowed;
• Child has received any live vaccine within 28 days of the study vaccine or is scheduled to receive live vaccine during the study period;
• Child has received any inactivated vaccine within 14 days of the study vaccine;
• Child is or will be enrolled in any other clinical trial of a drug, vaccine or medical device during the study period.